COVID-19 mRNA Vaccines as Antigen-Agnostic Immunomodulators: A Repurposing Perspective
Medical Sciences · 2026
DOI: 10.3390/medsci14050572 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Sciences, 2026. Verfasst von Piercarlo Minoretti und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Social Sciences, Miguel de Cervantes European University (UEMC), 47012 Valladolid, Spain. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Drug Repositioning, Immunologic Factors. Die Arbeit nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Since 2020, billions of doses of COVID-19 messenger RNA (mRNA) lipid nanoparticle vaccines have been administered worldwide, generating one of the largest pharmacovigilance databases for a modern therapeutic class. Intriguingly, their immunopharmacologic profile—including the engagement of innate nucleic acid sensors, systemic type I interferon signaling, dendritic cell-mediated cross-priming of CD8+ T cells, and upregulation of programmed cell death ligand 1 (PD-L1)—may extend beyond COVID-19 prophylaxis. Retrospective evidence from six independent cohorts, one of which is a multinational health-data network, indicated that vaccination within 100 days of immune checkpoint inhibitor (ICI) initiation may improve survival of patients with malignancies, including in immunologically cold tumors, although a substantial fraction of the original effect may be attributed to pandemic-era selection bias. Here, we examine the mechanistic basis and available evidence for the repurposing of licensed COVID-19 mRNA vaccines as antigen-agnostic immunomodulators. We identified five candidate contexts for prospective evaluation—namely, (1) PD-L1-negative non-small cell lung cancer initiating ICI therapy, (2) perioperative immune dysfunction in major cardiac surgery, (3) chronic hepatitis B, (4) chronic HIV with persistent immune exhaustion, and (5) sepsis-induced immunoparalysis. Methodological foundations for confirmatory assessment—comprising target trial emulation, Mendelian randomization, and pragmatic trial design—are now sufficiently developed to enable implementation. Prospective evaluation of the antigen-agnostic repurposing hypothesis is operationally feasible, albeit constrained by residual confounding and uncertainty about the durability of vaccine-induced innate reprogramming.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Social Sciences, Miguel de Cervantes European University (UEMC), 47012 Valladolid, Spain.
- Studio Minoretti, I-23848 Oggiono, LC, Italy.
- 2E Science, I-27038 Robbio, PV, Italy.
ORCID-Profile: Piercarlo Minoretti, Enzo Emanuele
Zitieren
APA
Minoretti, P., & Emanuele, E. (2026). COVID-19 mRNA Vaccines as Antigen-Agnostic Immunomodulators: A Repurposing Perspective. Medical Sciences. https://doi.org/10.3390/medsci14050572
Vancouver
Minoretti P, Emanuele E. COVID-19 mRNA Vaccines as Antigen-Agnostic Immunomodulators: A Repurposing Perspective. Medical Sciences. 2026. doi:10.3390/medsci14050572
BibTeX
@article{Minoretti2026,
author = {Minoretti, Piercarlo and Emanuele, Enzo},
title = {COVID-19 mRNA Vaccines as Antigen-Agnostic Immunomodulators: A Repurposing Perspective},
journal = {Medical Sciences},
year = {2026},
doi = {10.3390/medsci14050572}
}
EUVIMED